Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
FOLH1 encodes a type II transmembrane glycoprotein belonging to the M28 peptidase family. Additionally we are shipping PSMA Antibodies (237) and PSMA Kits (5) and many more products for this protein.
Showing 10 out of 23 products:
PSMA, TERT, and PDEF may serve as a reference for clinical diagnosis and as potential targets for the malignant tumor of the prostate therapeutics
Furthermore, the results also demonstrate that the stability of GCPII protein is regulated by HDAC1 (show HDAC1 Proteins) through acetylation at the lysine 479 residue.
Results provide evidence that PSMA is expressed in the neovasculature of a subset of soft tissue tumors to a variable extent predominantly occurring in sarcomas.
PSMA is significantly overexpressed in the neovasculature of differentiated thyroid cancers compared with normal and benign thyroid nodules
Demonstrate that several laminin-derived peptides containing carboxy-terminal glutamate (show GRIN1 Proteins) moieties (LQE, IEE, LNE) are bona fide substrates for PSMA. Subsequently, the peptide products were tested for their effects on angiogenesis in various models.
results demonstrate both the feasibility of preparing PSMA-targeted MBs (show PPP1R12A Proteins) and the benefits of using bioorthogonal chemistry to create targeted US probes
Xenografted human tumors expressing different levels of prostate-specific membrane antigen (PSMA) was produced to assess the clearance, biodistribution and imaging potential of 123I-scFvD2B.
GCPII may not be a priority target for molecular imaging of atherosclerotic lesions.
We also confirmed the specificity and selectivity of prostate-specific membrane antigen targeting by assessing prostate-specific membrane antigen-null PC3 (show PCSK1 Proteins) cell lines under the same conditions (<10% cell ablation
In conclusion, we have successfully developed the specific PSMA-targeting IO nanoparticle, DOTA-IO-GUL, as a dual-modality probe for complementary PET/MR imaging
Tissues such as prostate and testes exhibit different GCPII expression levels among the species studied (human, rats, swine).
intestinal GCPII and intestinal and hepatic RFC (show SLC19A1 Proteins) all exhibit ontogenic changes in the pig that are reflected in postnatal folate status
Data support the hypothesis that the neuroprotective efficacy of glutamate carboxypeptidase II knockout in traumatic brain injury is mediated via a reduction in oxidative stress.
Knockout of the GCPII gene is not embryonic lethal and affords histopathological protection with improved long-term behavioral outcomes after traumatic brain injury
Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
PSMA plays a VEGF (show VEGFA Proteins)-independent role in retinal angiogenesis
The combined effects of a haplo-insufficiency of glutamate carboxypeptidase II and dietary folic acid deficiency esult in reciprocal protection against cognitive and social deficits.
analysis of GCP2 and GCP3; beta-citrylglutamate hydrolase is glutamate carboxypeptidase 3
active PSMA facilitates integrin signaling and PAK activation, leading to both productive invasion and downregulation of integrin beta(1 (show ITGB1 Proteins)) signaling via reduced PSMA activity
This study demenestrated that the heterozygous mice,glutamate carboxypeptidase II, however, developed normally to adulthood and exhibited increased locomotor activity, reduced social interaction, and a subtle cognitive deficit in working memory.
This gene encodes a type II transmembrane glycoprotein belonging to the M28 peptidase family. The protein acts as a glutamate carboxypeptidase on different alternative substrates, including the nutrient folate and the neuropeptide N-acetyl-l-aspartyl-l-glutamate and is expressed in a number of tissues such as prostate, central and peripheral nervous system and kidney. A mutation in this gene may be associated with impaired intestinal absorption of dietary folates, resulting in low blood folate levels and consequent hyperhomocysteinemia. Expression of this protein in the brain may be involved in a number of pathological conditions associated with glutamate excitotoxicity. In the prostate the protein is up-regulated in cancerous cells and is used as an effective diagnostic and prognostic indicator of prostate cancer. This gene likely arose from a duplication event of a nearby chromosomal region. Alternative splicing gives rise to multiple transcript variants encoding several different isoforms.
folate hydrolase 1
, glutamate carboxypeptidase 2
, folate hydrolase (prostate-specific membrane antigen) 1
, glutamate carboxypeptidase 2-like
, N-acetylated alpha-linked acidic dipeptidase 1
, N-acetylated-alpha-linked acidic dipeptidase I
, NAALADase I
, cell growth-inhibiting gene 27 protein
, folylpoly-gamma-glutamate carboxypeptidase
, glutamate carboxylase II
, glutamate carboxypeptidase II
, membrane glutamate carboxypeptidase
, prostate specific membrane antigen variant F
, pteroylpoly-gamma-glutamate carboxypeptidase
, prostate-specific membrane antigen homolog
, prostate-specific membrane antigen
, N-acetylated alpha-linked acidic dipeptidase